Recent Quotes

My Watchlist

Indicators

Currencies

International

Treasuries

Cadrenal Therapeutics, Inc. - Common Stock (NQ:CVKD)

6.890 +0.680 (+10.95%)

Streaming Delayed Price Updated: 3:36 PM EST, Feb 20, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	79,770
Open	6.410
Bid (Size)	6.800 (100)
Ask (Size)	6.950 (100)
Prev. Close	6.210
Today's Range	6.170 - 7.255
52wk Range	4.910 - 22.90
Shares Outstanding	16,008,469
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Why Is Cadrenal Therapeutics Stock Drawing Retail Attention Today? ↗

January 19, 2026

The company said VLX-1005 targets a high-risk heparin complication with limited treatment options.

Via Stocktwits

Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System

December 30, 2025

Via ACCESS Newswire

Performance

YTD	-6.0%	-6.0%
1 Month	-6.5%	-6.5%
3 Month	-39.0%	-39.0%
6 Month	-44.7%	-44.7%
1 Year	-64.7%	-64.7%

More News

Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On

December 29, 2025

Via ACCESS Newswire

Cadrenal's Quiet Expansion Play Is Starting to Get Loud

December 12, 2025

Via ACCESS Newswire

Cadrenal Therapeutics Expands Pipeline With Portfolio Acquisition Worth Up To $15 Million ↗

September 15, 2025

Via Stocktwits

Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market

December 12, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

September 17, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

September 10, 2025

Via Benzinga

Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 11, 2025

From Cadrenal Therapeutics, Inc.

Via Business Wire

Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis

August 05, 2025

From Cadrenal Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

July 15, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

July 14, 2025

Via Benzinga

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

June 12, 2025

From Cadrenal Therapeutics, Inc.

Via Business Wire

Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025

June 04, 2025

From Cadrenal Therapeutics, Inc.

Via Business Wire

Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness

May 15, 2025

From Cadrenal Therapeutics, Inc.

Via Business Wire

$34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thiner, Less Problematic Than Warfrain: Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)

May 13, 2025

Via Get News

Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

May 08, 2025

From Cadrenal Therapeutics, Inc.

Via Business Wire

Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

April 03, 2025

From Cadrenal Therapeutics, Inc.

Via Business Wire

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

March 13, 2025

From Cadrenal Therapeutics, Inc.

Via Business Wire

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

March 04, 2025

From Cadrenal Therapeutics, Inc.

Via Business Wire

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

February 06, 2025

From Cadrenal Therapeutics, Inc.

Via Business Wire

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference

February 05, 2025

From Cadrenal Therapeutics, Inc.

Via Business Wire

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

January 09, 2025

From Cadrenal Therapeutics, Inc.

Via Business Wire

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications

December 31, 2024

From Cadrenal Therapeutics

Via Business Wire

Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

December 18, 2024

From Cadrenal Therapeutics, Inc.

Via Business Wire

Frequently Asked Questions

Is Cadrenal Therapeutics, Inc. - Common Stock publicly traded?

Yes, Cadrenal Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Cadrenal Therapeutics, Inc. - Common Stock trade on?

Cadrenal Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Cadrenal Therapeutics, Inc. - Common Stock?

The ticker symbol for Cadrenal Therapeutics, Inc. - Common Stock is CVKD on the Nasdaq Stock Market

What is the current price of Cadrenal Therapeutics, Inc. - Common Stock?

The current price of Cadrenal Therapeutics, Inc. - Common Stock is 6.890

When was Cadrenal Therapeutics, Inc. - Common Stock last traded?

The last trade of Cadrenal Therapeutics, Inc. - Common Stock was at 02/20/26 03:36 PM ET

What is the market capitalization of Cadrenal Therapeutics, Inc. - Common Stock?

The market capitalization of Cadrenal Therapeutics, Inc. - Common Stock is 110.30M

How many shares of Cadrenal Therapeutics, Inc. - Common Stock are outstanding?

Cadrenal Therapeutics, Inc. - Common Stock has 110M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.